Everest Clinical Research

ecrscorp.com

Everest Clinical Research ("Everest"​) is a full-service contract research organization (CRO) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

CEDARS-SINAI MEDICAL CENTER AND AIKIDO PHARMA INC. TO CODEVELOP NOVEL IMMUNO-ONCOLOGY CANCER TREATMENT

AIkido Pharma Inc. | March 15, 2022

news image

AIkido Pharma Inc. announced that the Company and Cedars-Sinai Medical Center have agreed under their Master Collaboration Agreement to co-fund and codevelop a novel immuno-oncology treatment designed to promote the destruction of cancer cells by a patient's own "killer" T-cells. The Company and Cedars-Sinai will share costs, expenses and management of the drug co-development and will leverage the talent of Cedars-Sinai Technology Ventures and the lead scientists who...

Read More

Pharma Tech

ANTENGENE ANNOUNCES CLINICAL TRIAL COLLABORATION WITH BEIGENE TO EVALUATE SELINEXOR IN COMBINATION WITH TISLELIZUMAB IN T AND NK-CELL LYMPHOMA

Antengene Corporation Limited | June 27, 2022

news image

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizum...

Read More

Pharma Tech

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Pfizer | December 21, 2020

news image

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More

Pharmacy Market

POINT BIOPHARMA AND ADVANCELL TO COLLABORATE IN THE DEVELOPMENT OF LEAD-212-LABELED RADIOLIGANDS

Globenewswire | June 27, 2023

news image

POINT Biopharma Global Inc. a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and AdvanCell, a company developing an innovative pipeline of targeted alpha therapies with a platform technology to produce 212Pb radiopharmaceuticals, today announced a collaboration on the development of a global 212Pb radioisotope and radioligand supply chain and drug manufacturing network to specifically support the clinical development and commercial...

Read More
news image

Business Insights

CEDARS-SINAI MEDICAL CENTER AND AIKIDO PHARMA INC. TO CODEVELOP NOVEL IMMUNO-ONCOLOGY CANCER TREATMENT

AIkido Pharma Inc. | March 15, 2022

AIkido Pharma Inc. announced that the Company and Cedars-Sinai Medical Center have agreed under their Master Collaboration Agreement to co-fund and codevelop a novel immuno-oncology treatment designed to promote the destruction of cancer cells by a patient's own "killer" T-cells. The Company and Cedars-Sinai will share costs, expenses and management of the drug co-development and will leverage the talent of Cedars-Sinai Technology Ventures and the lead scientists who...

Read More
news image

Pharma Tech

ANTENGENE ANNOUNCES CLINICAL TRIAL COLLABORATION WITH BEIGENE TO EVALUATE SELINEXOR IN COMBINATION WITH TISLELIZUMAB IN T AND NK-CELL LYMPHOMA

Antengene Corporation Limited | June 27, 2022

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizum...

Read More
news image

Pharma Tech

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Pfizer | December 21, 2020

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More
news image

Pharmacy Market

POINT BIOPHARMA AND ADVANCELL TO COLLABORATE IN THE DEVELOPMENT OF LEAD-212-LABELED RADIOLIGANDS

Globenewswire | June 27, 2023

POINT Biopharma Global Inc. a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and AdvanCell, a company developing an innovative pipeline of targeted alpha therapies with a platform technology to produce 212Pb radiopharmaceuticals, today announced a collaboration on the development of a global 212Pb radioisotope and radioligand supply chain and drug manufacturing network to specifically support the clinical development and commercial...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us